AstraZeneca PLC American Depositary Shares (AZN)
CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street
AstraZeneca is delisting its American Depositary Receipts from the Nasdaq, replacing them with a direct listing of ordinary shares on the New York Stock Exchange. At first blush, it confirms fears first aired when, in July, The Times reported that CEO Pascal Soriot wanted to move AZ's stock market listing to the U.S.
AstraZeneca's US listing may pull other firms from London in its wake
AstraZeneca's move to upgrade its listing in the U.S. risks pulling liquidity away from London's stock market and could pave the way for other large companies to follow suit, analysts, investors and advisers said.
AstraZeneca to directly list shares in New York, retain UK listing
AstraZeneca said on Monday that it will now directly list its shares on the New York Stock Exchange, instead of the current depository shares, adding that it will continue to be listed and headquartered in the UK.
AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices
AstraZeneca said it will offer its asthma and diabetes drugs at an up to 70% discount in the U.S. ahead of a Trump administration deadline for pharmaceutical companies to cut drug prices.
Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
The latest trading day saw Astrazeneca (AZN) settling at $73.53, representing a -2.43% change from its previous close.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors
Even with Trump's looming threats to impose tariffs on pharma imports, the performance of AstraZeneca's cardiovascular and oncology franchises continues to impress me. So, sales of Truqap, which continues to actively capture the breast cancer drugs market, reached $170 million in the second quarter of 2025, an increase of 84.8% year-on-year. Despite AstraZeneca's aggressive R&D policy, its EBIT margin was 24.1% in Q2 2025, up 2.9% year-on-year.
AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire
AstraZeneca wins CHMP backing for label expansions of Koselugo in adult NF1 PN patients and Tezspire in chronic rhinosinusitis with nasal polyps.
AstraZeneca lupus drug Saphnelo shows promise in self-injection trial
AstraZeneca PLC (LSE:AZN) has reported positive results from a late-stage study of Saphnelo, its treatment for systemic lupus erythematosus (SLE), showing the drug was effective when given as a self-administered injection under the skin. The phase III TULIP-SC trial met its main goal at an interim analysis, demonstrating that patients receiving subcutaneous Saphnelo had a statistically significant and clinically meaningful reduction in disease activity compared with placebo.
AstraZeneca's asthma drug fails main goal of COPD study
AstraZeneca said on Wednesday that its asthma drug Fasenra failed the main goal of a late-stage study in patients with chronic obstructive pulmonary disease (COPD).
AstraZeneca shares down 3% after rating cut, UK investment pause
AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in its home market.
AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
The company has shelved plans for a research facility in Cambridge, a move that follows the drugmaker in January scrapping an investment in Liverpool.
